Pittsburgh Development Center, 204 Craft Avenue, Pittsburgh, PA 15213, USA.
Stem Cell Res Ther. 2010 Aug 5;1(3):24. doi: 10.1186/scrt24.
The study of pluripotent stem cells has generated much interest in both biology and medicine. Understanding the fundamentals of biological decisions, including what permits a cell to maintain pluripotency, that is, its ability to self-renew and thereby remain immortal, or to differentiate into multiple types of cells, is of profound importance. For clinical applications, pluripotent cells, including both embryonic stem cells and adult stem cells, have been proposed for cell replacement therapy for a number of human diseases and disorders, including Alzheimer's, Parkinson's, spinal cord injury and diabetes. One challenge in their usage for such therapies is understanding the mechanisms that allow the maintenance of pluripotency and controlling the specific differentiation into required functional target cells. Because of regulatory restrictions and biological feasibilities, there are many crucial investigations that are just impossible to perform using pluripotent stem cells (PSCs) from humans (for example, direct comparisons among panels of inbred embryonic stem cells from prime embryos obtained from pedigreed and fertile donors; genomic analysis of parent versus progeny PSCs and their identical differentiated tissues; intraspecific chimera analyses for pluripotency testing; and so on). However, PSCs from nonhuman primates are being investigated to bridge these knowledge gaps between discoveries in mice and vital information necessary for appropriate clinical evaluations. In this review, we consider the mRNAs and novel genes with unique expression and imprinting patterns that were discovered using systems biology approaches with primate pluripotent stem and germ cells.
多能干细胞的研究在生物学和医学领域都引起了极大的兴趣。了解生物学决策的基本原理,包括允许细胞维持多能性的因素,即细胞自我更新和保持永生的能力,或者分化为多种类型的细胞,具有深远的重要意义。对于临床应用,多能细胞,包括胚胎干细胞和成人干细胞,已被提议用于多种人类疾病和障碍的细胞替代治疗,包括阿尔茨海默病、帕金森病、脊髓损伤和糖尿病。在将其用于此类治疗时的一个挑战是理解允许维持多能性的机制,并控制特定分化为所需功能靶细胞。由于监管限制和生物学可行性,有许多关键的研究使用来自人类的多能干细胞 (PSCs) 是不可能完成的(例如,直接比较来自有血统和生育能力的供体的优质胚胎的同系胚胎干细胞的面板;PSC 及其相同分化组织的亲本与后代的基因组分析;用于多能性测试的种内嵌合体分析;等等)。然而,正在研究来自非人类灵长类动物的 PSCs,以弥合在小鼠中发现的发现与适当临床评估所需的重要信息之间的知识空白。在这篇综述中,我们考虑了使用灵长类多能干细胞和生殖细胞的系统生物学方法发现的具有独特表达和印记模式的 mRNAs 和新基因。